Abionyx Pharma (ABNX.FP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Euronext FR]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Euronext FR]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Accounts receivable | -81 | 384 | 36 | -95 | 0 |
| Other Working Capital | -28 | 538 | 97 | -1,744 | 2,130 |
| Other Operating Activity | -3,525 | -4,620 | -3,492 | -4,853 | -2,729 |
| Operating Cash Flow | $-3,634 | $-3,698 | $-3,359 | $-6,692 | $-599 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -68 | -104 | -165 | -163 | -80 |
| Purchase Sale Intangibles | -8 | -26 | -10 | 0 | -45 |
| Other Investing Activity | 0 | 0 | 0 | 1,501 | 0 |
| Investing Cash Flow | $-76 | $-130 | $-175 | $1,338 | $-125 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -490 | -300 | -236 | -19 | -200 |
| Common Stock Issued | 3,358 | 4,186 | 42 | 4,056 | 1,836 |
| Common Stock Repurchased | -24 | N/A | N/A | -65 | -89 |
| Financing Cash Flow | $2,844 | $3,886 | $-194 | $3,972 | $1,547 |
| Beginning Cash Position | 4,102 | 4,044 | 7,772 | 9,154 | 8,331 |
| End Cash Position | 3,235 | 4,102 | 4,044 | 7,772 | 9,154 |
| Net Cash Flow | $-866 | $58 | $-3,728 | $-1,382 | $823 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,634 | -3,698 | -3,359 | -6,692 | -599 |
| Capital Expenditure | -76 | -130 | -175 | -166 | -148 |
| Free Cash Flow | -3,710 | -3,828 | -3,534 | -6,858 | -747 |